Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order through Physicians
Labcorp (NYSE: LH) has launched a new commercial H5 bird flu molecular test in the United States to diagnose human infections with H5N1 virus. The test development, supported by the CDC, comes amid a multistate outbreak affecting poultry and dairy cows, with recent human cases reported in dairy and poultry workers. Healthcare providers can now order the test for suspected cases, collecting nasopharyngeal swab specimens for PCR analysis.
While current public health risk remains low, the test enhances testing infrastructure and supports public health preparedness. The CDC is monitoring human cases, and the USDA is conducting surveillance of milk supply and dairy herds. This initiative follows Labcorp's previous collaborations with CDC on testing for emerging viruses like Zika, COVID-19, and mpox.
Labcorp (NYSE: LH) ha lanciato un nuovo test molecolare commerciale per l'influenza aviaria H5 negli Stati Uniti, per diagnosticare le infezioni umane da virus H5N1. Lo sviluppo del test, supportato dai CDC, arriva in un contesto di focolai multistatali che interessano pollame e mucche da latte, con recenti casi umani segnalati tra i lavoratori del latte e del pollame. I fornitori di servizi sanitari possono ora ordinare il test per casi sospetti, prelevando campioni di tampone nasofaringeo per l'analisi PCR.
Sebbene il rischio attuale per la salute pubblica rimanga basso, il test migliora l'infrastruttura di testing e supporta la preparazione per la salute pubblica. I CDC stanno monitorando i casi umani e il USDA sta conducendo sorveglianza sulla fornitura di latte e sugli allevamenti di latte. Questa iniziativa segue le precedenti collaborazioni di Labcorp con i CDC sui test per virus emergenti come Zika, COVID-19 e mpox.
Labcorp (NYSE: LH) ha lanzado una nueva prueba molecular comercial para la gripe aviar H5 en los Estados Unidos para diagnosticar infecciones humanas por el virus H5N1. El desarrollo de la prueba, respaldado por los CDC, se produce en medio de un brote multiestatal que afecta a aves de corral y vacas lecheras, con recientes casos humanos reportados entre trabajadores de productos lácteos y aves de corral. Los proveedores de atención médica ahora pueden ordenar la prueba para casos sospechosos, recolectando muestras de hisopos nasofaríngeos para análisis de PCR.
Aunque el riesgo actual para la salud pública se mantiene bajo, la prueba mejora la infraestructura de pruebas y apoya la preparación de salud pública. Los CDC están monitoreando los casos humanos y el USDA está realizando vigilancia sobre el suministro de leche y los rebaños lecheros. Esta iniciativa sigue las colaboraciones anteriores de Labcorp con los CDC en pruebas para virus emergentes como Zika, COVID-19 y mpox.
Labcorp (NYSE: LH)는 미국에서 H5N1 바이러스로 인한 인간 감염을 진단하기 위한 상업적 H5 조류 독감 분자 검사를 출시했습니다. 질병 통제 예방 센터(CDC)의 지원을 받은 이 검사 개발은 가금류와 유제품에서 다수의 주에 걸쳐 발생한 발병 가운데 진행되며, 최근 유제품과 가금류 작업자들에서 인간 사례가 보고되었습니다. 의료 제공자는 이제 의심 사례에 대해 검사를 주문하고 PCR 분석을 위한 비인두 면봉 샘플을 수집할 수 있습니다.
현재 공공 건강 위험이 낮게 유지되고 있지만, 이 검사는 검사 인프라를 강화하고 공공 건강 준비 상태를 지원합니다. CDC는 인간 사례를 모니터링하고 있으며 USDA는 우유 공급 및 유제품 군에 대한 감시를 수행하고 있습니다. 이 이니셔티브는 Labcorp이 Zika, COVID-19 및 mpox와 같은 신종 바이러스에 대한 검사를 CDC와 이전에 협력한 결과입니다.
Labcorp (NYSE: LH) a lancé un nouveau test moléculaire commercial pour la grippe aviaire H5 aux États-Unis afin de diagnostiquer les infections humaines par le virus H5N1. Le développement du test, soutenu par les CDC, intervient dans le cadre d'une épidémie multistatique touchant les volailles et les vaches laitières, avec des cas humains récents signalés chez des travailleurs du lait et de la volaille. Les prestataires de soins de santé peuvent désormais commander le test pour des cas suspects, en prélevant des échantillons d'écouvillon nasopharyngé pour une analyse PCR.
Bien que le risque actuel pour la santé publique reste faible, le test améliore l'infrastructure de test et soutient la préparation de la santé publique. Les CDC surveillent les cas humains, et le USDA effectue une surveillance de l'approvisionnement en lait et des troupeaux laitiers. Cette initiative fait suite aux précédentes collaborations de Labcorp avec les CDC sur les tests de virus émergents tels que Zika, COVID-19 et mpox.
Labcorp (NYSE: LH) hat in den Vereinigten Staaten einen neuen kommerziellen molekularen Test auf Vogelgrippe H5 zur Diagnose menschlicher Infektionen mit dem H5N1-Virus eingeführt. Die Entwicklung des Tests, die von den CDC unterstützt wird, erfolgt im Rahmen eines mehrstaatlichen Ausbruchs, der Geflügel und Milchkühe betrifft, wobei kürzlich menschliche Fälle unter Milch- und Geflügelarbeitern gemeldet wurden. Gesundheitsdienstleister können jetzt den Test für Verdachtsfälle anordnen und nasopharyngeale Abstrichproben zur PCR-Analyse entnehmen.
Obwohl das derzeitige öffentliche Gesundheitsrisiko niedrig bleibt, verbessert der Test die Testinfrastruktur und unterstützt die Vorbereitung auf die öffentliche Gesundheit. Die CDC überwacht menschliche Fälle, und das USDA führt Überwachungen der Milchversorgung und der Milchherden durch. Diese Initiative folgt Labcorps früheren Kooperationen mit den CDC bei Tests für aufkommende Viren wie Zika, COVID-19 und mpox.
- Commercial launch of new H5 bird flu diagnostic test expands company's testing portfolio
- Strategic collaboration with CDC strengthens market position in infectious disease testing
- Test addresses emerging market need amid current outbreak in multiple states
- Test not available in New York State market
- Revenue impact uncertain due to currently low public health risk
Insights
Labcorp's new H5 bird flu test marks a significant advancement in infectious disease diagnostics and public health infrastructure. The PCR-based molecular test provides critical early detection capabilities for H5N1 infections in humans, particularly important given the current multistate outbreak in poultry and dairy cows. The test's commercial availability through physicians enhances the national surveillance system and preparedness strategy.
The collaboration with the CDC adds credibility and ensures alignment with public health protocols. While current human infection risk remains low, the test's deployment is a proactive measure that strengthens the healthcare system's ability to monitor and respond to potential human cases, especially among high-risk groups like dairy and poultry workers. The test's integration into Labcorp's extensive laboratory network ensures widespread accessibility and rapid result reporting.
This product launch strategically positions Labcorp to capture market share in emerging infectious disease diagnostics. The timing is particularly advantageous given the ongoing H5N1 outbreak in the agricultural sector. By developing this test with CDC support, Labcorp demonstrates its capability to respond quickly to public health needs and strengthens its relationship with key government stakeholders.
The commercial availability of this test could drive additional revenue streams, especially if H5N1 cases increase or testing becomes routine for at-risk populations. It also reinforces Labcorp's market leadership in infectious disease testing, following their successful deployments for Zika, COVID-19 and mpox. This expansion of their diagnostic portfolio enhances their competitive position and could positively impact their market valuation.
New test supports public health preparedness efforts and testing infrastructure amid multistate outbreak of H5 bird flu in poultry and dairy cows
The test launch comes amid a multistate outbreak of H5 bird flu in poultry and dairy cows, with several recent human cases in
Labcorp developed this commercially available test with support from the CDC to increase access and testing capacity to support public health preparedness strategies.
"As we continue to monitor developments related to the H5N1 virus, Labcorp is dedicated to equipping healthcare providers with the critical diagnostic tools they need to address emerging infectious disease threats," said Marcia Eisenberg, Ph.D., chief scientific officer at Labcorp. "By leveraging Labcorp's scientific expertise and extensive testing capacity, we are contributing to a proactive public health preparedness strategy, putting testing resources and infrastructure in place to detect and respond to human cases of H5 bird flu."
Healthcare providers suspecting patients of H5 bird flu infection can collect a nasopharyngeal swab specimen at the point of care and submit it to Labcorp for analysis. Labcorp's test uses polymerase chain reaction (PCR) technology and a specific reagent validated to determine the presence of the H5 virus genetic material. Results are reported to the patient and physician.
Labcorp's collaboration with the CDC on the H5 bird flu test is the latest in a series of collaborations that have provided testing infrastructure and capacity for emerging viruses that cause infectious diseases in humans, including Zika, SARS-CoV-2 (COVID-19) and mpox.
To learn more, visit https://www.labcorp.com/tests/140046/influenza-a-and-influenza-b-with-reflex-to-h5-subtyping-naa.
*Test not yet available in
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-launches-h5-bird-flu-test-in-the-us-now-available-for-order-through-physicians-302333679.html
SOURCE Labcorp
FAQ
What is Labcorp's new H5 bird flu test and when was it launched?
How does Labcorp's H5N1 test work for patients?
Where is Labcorp's H5 bird flu test available?
What is the significance of Labcorp's H5 test amid current outbreaks?
How does this test align with Labcorp's previous infectious disease testing?
